GenMark Diagnostics, Inc
GNMK
GNMK was delisted on the 21st of April, 2021.
77 hedge funds and large institutions have $380M invested in GenMark Diagnostics, Inc in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 30 increasing their positions, 23 reducing their positions, and 11 closing their positions.
66% more capital invested
Capital invested by funds: $230M → $380M (+$150M)
30% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 23
4% less call options, than puts
Call options by funds: $97K | Put options by funds: $101K
10% less funds holding
Funds holding: 86 → 77 (-9)
73% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
+$3.5M |
| 2 |
Morgan Stanley
New York
|
+$3.46M |
| 3 |
CC
Casdin Capital
New York
|
+$2.85M |
| 4 |
CCM
Cadian Capital Management
New York
|
+$1.65M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$856K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$3.46M |
| 2 |
VAM
Visium Asset Management
New York
|
-$1.82M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.67M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$1.58M |
| 5 |
Jennison Associates
New York
|
-$1.17M |
GNMK Hedge Fund Activity: Q2 2016 in Review
77 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in GenMark Diagnostics, Inc (GNMK) for Q2 2016, worth a combined $380M — up 66% from $230M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of GNMK and 3 opened new positions — a net loss of 8 holders — while 23 trimmed existing stakes and 30 added.
The largest buyer was Northpointe Capital, adding an estimated $3.5M. The largest seller was Putnam Investments, cutting an estimated $3.46M.
- 77 institutional investors held GenMark Diagnostics, Inc (GNMK) as of Q2 2016, down from 86 in Q1 2016.
- Funds reported $380M of GenMark Diagnostics, Inc stock for Q2 2016, up 66% quarter-over-quarter.
- 3 funds opened new GenMark Diagnostics, Inc positions in Q2 2016 and 11 closed out, a net change of -8 holders.
- The largest GenMark Diagnostics, Inc buyer in Q2 2016 was Northpointe Capital, an estimated $3.5M added.
- The largest GenMark Diagnostics, Inc seller in Q2 2016 was Putnam Investments, an estimated $3.46M sold.
Based on aggregated 13F filings for Q2 2016.